Paul M. Barr, M.D.

Paul M. Barr, M.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester, NY 14642

Professional Bio

Paul M. Barr, M.D. is an Assistant Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Center.





Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at Case Western Reserve University. He subsequently completed a hematology and oncology fellowship at Case Western and now holds subspecialty certification in Internal Medicine, Hematology and Oncology.

He is a member of the lymphoma committee in the Southwest Oncology Group and serves as principal investigator on several local and national clinical trial treatment protocols for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

His research interests focus on the development of novel therapeutics for patients with chronic lymphocytic leukemia and lymphoma. He has received a NIH funded K12 award during his training for his work with the organic amine Methoxyamine to improve the effect of fludarabine for CLL patients. Most recently, he was awarded a Clinical Research award from the Lymphoma Research Foundation based o his work developing combination therapies targeting molecules within the B cell receptor pathway for CLL and lymphoma patients.

Research Bio

Paul M. Barr, M.D. is an Assistant Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Center.



Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at Case Western Reserve University. He subsequently completed a hematology and oncology fellowship at Case Western and now holds subspecialty certification in Internal Medicine, Hematology and Oncology.

He is a member of the lymphoma committee in the Southwest Oncology Group and serves as principal investigator on several local and national clinical trial treatment protocols for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

His research interests focus on the development of novel therapeutics for patients with chronic lymphocytic leukemia and lymphoma. He has received a NIH funded K12 award during his training for his work with the organic amine Methoxyamine to improve the effect of fludarabine for CLL patients. Most recently, he was awarded a Clinical Research award from the Lymphoma Research Foundation based o his work developing combination therapies targeting molecules within the B cell receptor pathway for CLL and lymphoma patients.

Awards & Honors (National)

Lymphoma Research Foundation Clinical Investigator 2012 - 2015
NIH Loan Repayment Program Award Recipient | NIH 2011 - 2014
American Society of Hematology Clinical Research Training Institute 2009
NIH/NCI K12 Paul Calabresi Scholar | NIH | University Hospitals Case Medical Center, Case Western Resrve 2008

Awards & Honors (Local)

Wilmot Cancer Research Fellowship 2011 - 2014
John W. Harris, MD Hematology Scholar Award | Case Western Reserve University 2006 - 2007
Chief Medical Resident | Case Western Reserve University/University Hospitals 2003 - 2004

Recent Journal Articles

Showing the 5 most recent journal articles. 38 available »

2015 Aug 18
Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW. "Phase 1 Trial of Carfilzomib (PR-171) in Combination with Vorinostat (SAHA) in Patients with Relapsed or Refractory B-Cell Lymphomas." Leukemia & lymphoma. 2015 Aug 18; :1-30. Epub 2015 Aug 18.
2015 Aug
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. "Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma." Nature medicine. 2015 Aug; 21(8):922-6. Epub 2015 Jul 20.
2015 Jul 20
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. "Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jul 20; 33(21):2399-404. Epub 2015 Jun 15.
2015 May 7
Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S. "The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia." Blood. 2015 May 7; 125(19):2915-22. Epub 2015 Mar 09.
2015 Feb
Hutchinson K, Jahangiri S, Calvi LM, Barr P, Friedberg JW, Kelly JL. "Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma." Leukemia & lymphoma. 2015 Feb; 56(2):508-11. Epub 2014 Jul 15.

Current Appointments

Medical Director, Cancer Center Clinical Trials Office - Department of Medicine (SMD)
Assistant Professor - Department of Medicine, Hematology/Oncology (SMD) - Primary
Assistant Professor - Cancer Center

Specialties

Internal Medicine - American Board of Internal Medicine
Hematology - American Board of Internal Medicine
Medical Oncology - American Board of Internal Medicine

Education

MD | Medicine | Northeastern Ohio Univs Med Sch2000
BA | Zoology | Miami University-Oxford1996

Post-Doctoral Training & Residency

Fellowship in Hematology/Oncology at University Hospitals of Cleveland07/01/2004 - 06/30/2007
Residency in Internal Medicine at University Hospitals of Cleveland07/01/2001 - 06/30/2003
Internship in Internal Medicine at University Hospitals of Cleveland07/01/2000 - 06/30/2001